Serelaxin and the AT₂ Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil

Search results

• Finished

  Novel treatments of fibrosis for hypertensive heart disease

  Widdop, R. (Primary Chief Investigator (PCI)), Aguilar, M. (Chief Investigator (CI)) & Denton, K. (Chief Investigator (CI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/17 → 31/12/20

  Project: Research

• Understanding the cardio-protective actions of the AT2R in females: Shifting gears between AT1 and AT2 receptor balance of function with relaxin.

  Denton, K. (Primary Chief Investigator (PCI)), Samuel, C. (Chief Investigator (CI)), Widdop, R. (Chief Investigator (CI)), Hewitson, T. (Chief Investigator (CI)) & Pearson, J. (Chief Investigator (CI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/16 → 31/12/19

  Project: Research

• Defining nonclassical angiotensin signalling and cardiovascular function

  Widdop, R. (Primary Chief Investigator (PCI)), Aguilar, M. (Chief Investigator (CI)), Denton, K. (Chief Investigator (CI)) & Perlmutter, P. (Chief Investigator (CI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/13 → 31/12/15

  Project: Research

• NHMRC Research Fellowship

  Samuel, C. (Primary Chief Investigator (PCI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/13 → 31/12/18

  Project: Research

• NHMRC Research Fellowship

  Denton, K. (Primary Chief Investigator (PCI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/08 → 31/12/17

  Project: Research